AI Article Synopsis
Article Abstract
Objective: To assess the available clinical and economic evidence of erenumab vs onabotulinumtoxinA for chronic migraine (CM) and present de-novo indirect treatment comparisons (ITCs) based on available clinical trial data.
Methods: We conducted ITCs based on results from the pivotal 295 trial (NCT02066415) of erenumab vs placebo and published aggregate data from the PREEMPT 1 (NCT00156910) and PREEMPT 2 (NCT00168428) trials of onabotulinumtoxinA vs placebo. ITCs were conducted for CM patients with and without prior administration of onabotulinumtoxinA and among CM patients with ≥3 prior preventive treatment failures. Efficacy was assessed based on responder rates of ≥50% reductions in monthly headache days (MHDs) and monthly migraine days (MMDs) as well as change from baseline in both MHDs and MMDs.
Results: Among patients with CM, 140 mg erenumab was associated with a reduction of 1.2 MHD ( = .092) and a reduction of 1.0 MMD ( = .174) compared to onabotulinumtoxinA at Week 12. Among onabotulinumtoxinA-naïve patients, erenumab was associated with a reduction of 1.8 MHD ( = .026) and 1.4 MMD ( = .080) at Week 12. Among patients that had received ≥3 prior preventive treatments, the odds ratios comparing erenumab vs onabotulinumtoxinA were 1.7 for ≥50% responder rates based on reductions in MHD ( = .155) and 1.7 for ≥50% responder rates based on reductions in MMD ( = .140).
Conclusion: These findings suggest directional benefits (although not reaching the threshold of statistical significance) associated with erenumab vs onabotulinumtoxinA for the preventive treatment of CM. Evidence from this study may inform healthcare stakeholders in treatment selection and optimization for patients with CM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03007995.2022.2131299 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling.
Health Technol Assess
October 2024
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.
Article Synopsis
- Chronic migraine affects 2-4% of adults globally and recent advances in expensive medications have prompted a review of their clinical and cost-effectiveness.
- The study analyzed data from randomised controlled trials involving 7352 adults and compared six different medications, including calcitonin gene-related peptide monoclonal antibodies, Botox, and topiramate, against placebo.
- Results showed that calcitonin gene-related peptide monoclonal antibodies ranked highest in reducing headache days and improving quality of life, while topiramate was less effective compared to these newer treatments.
Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA.
Brain Sci
August 2024
School for Environment and Sustainability, University of Michigan, Ann Arbor, MI 48109, USA.
This retrospective study assesses the efficacy and tolerability of anti-calcitonin gene-related peptide (anti-CGRP) therapy in adolescents and young adults (ages 12-21) with migraine and chronic daily headaches unresponsive to standard treatments. Migraines in this demographic significantly impair school performance, self-esteem, psychological well-being, and cognitive health. These young patients are also particularly sensitive to the side effects of conventional medications, which are often prescribed off-label and come with high insurance denial rates.
View Article and Find Full Text PDFPsychopathological variables in chronic migraine patients with different therapeutic approach: psychological profile differences and impact on therapeutic efficacy in real life.
Neurol Sci
December 2024
Department of Medicine and Surgery, Unit of Headache and Neurosonology, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo 21, 00128, Rome, Italy.
Article Synopsis
- - The study investigates the differences in psychopathological conditions between chronic migraine patients treated with anti-CGRP monoclonal antibodies (SPECIFIC group) and those using onabotulinumtoxin-A or oral medications (NON-SPECIFIC group).
- - Results show that patients in the NON-SPECIFIC group had greater difficulties with emotion regulation, alexithymia, and impulsiveness compared to those in the SPECIFIC group, who experienced better and more stable treatment outcomes over time.
- - Importantly, the presence of psychopathological comorbidities did not affect the efficacy of treatment, indicating that anti-CGRP therapies offer superior results for chronic migraine management.
Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features.
Headache
October 2024
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Objective: To develop machine learning models using patient and migraine features that can predict treatment responses to commonly used migraine preventive medications.
Background: Currently, there is no accurate way to predict response to migraine preventive medications, and the standard trial-and-error approach is inefficient.
Methods: In this cohort study, we analyzed data from the Mayo Clinic Headache database prospectively collected from 2001 to December 2023.
Reversion of chronic to episodic migraine in working age and botulinum toxin-resistant patients treated with fremanezumab: A real-life study.
Brain Behav
July 2024
Servicio de Farmacia Hospitalaria, Hospital Universitario Puerta del Mar, Cadiz, Spain.
Objectives: The objectives of this real-life study were to analyze the reversion of chronic migraine (CM) to episodic migraine (EM) with fremanezumab, evaluate its benefit on the symptomatology, and determine the influence of possible clinical features on the reversion.
Background: The clinical manifestations of CM have a high impact on the quality of life of patients, and monoclonal antibodies such as fremanezumab are used as prophylactic treatment.
Methods: Diagnosed CM patients treated for at least 3 months with monthly fremanezumab were interviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!